Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by Invesco Ltd.

Invesco Ltd. increased its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 2,419.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 615,048 shares of the biotechnology company's stock after buying an additional 590,639 shares during the quarter. Invesco Ltd. owned about 0.73% of Anavex Life Sciences worth $6,606,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its position in shares of Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company's stock valued at $242,000 after buying an additional 1,191 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Anavex Life Sciences by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,980 shares of the biotechnology company's stock valued at $193,000 after acquiring an additional 1,671 shares during the last quarter. Foster Victor Wealth Advisors LLC increased its stake in Anavex Life Sciences by 5.6% in the fourth quarter. Foster Victor Wealth Advisors LLC now owns 37,663 shares of the biotechnology company's stock worth $405,000 after purchasing an additional 2,000 shares during the period. Opus Capital Group LLC lifted its position in shares of Anavex Life Sciences by 6.1% during the fourth quarter. Opus Capital Group LLC now owns 34,700 shares of the biotechnology company's stock worth $373,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Nwam LLC boosted its stake in shares of Anavex Life Sciences by 0.3% during the fourth quarter. Nwam LLC now owns 913,051 shares of the biotechnology company's stock valued at $9,806,000 after purchasing an additional 2,575 shares during the period. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Trading Down 1.7 %

Shares of NASDAQ:AVXL traded down $0.17 on Thursday, reaching $9.34. The company had a trading volume of 150,772 shares, compared to its average volume of 1,223,030. The firm has a market capitalization of $794.07 million, a PE ratio of -17.11 and a beta of 0.80. The firm's 50 day simple moving average is $8.85 and its 200-day simple moving average is $8.83. Anavex Life Sciences Corp. has a 52-week low of $3.51 and a 52-week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. As a group, equities research analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AVXL shares. D. Boral Capital reiterated a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday, April 7th. HC Wainwright reiterated a "buy" rating and issued a $42.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.